Vnitr Lek 2009, 55(Suppl 1):13-18
Hypertension therapy in obese patients
- II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
Inter-relationship between hypertension and obesity is very well known although the actual grounds for this linkage are not clear. There is growing evidence to support the role of increased sympathetic nervous system activity and involvement of the RAAS in aetiology of hypertension in obese patients. Visceral obesity is the type of obesity we should focus on in clinical practice. Treatment of hypertension should start with the treatment of obesity aiming at body weight reduction and changes to the lifestyle. Where indicated, lifestyle changes could, or even should, be supported with an anti-obesity agent. Positive effect of lifestyle management as well as anti-obesity agents on blood pressure reduction in obese patients has been established. Unfortunately, information about pharmacological management of hypertension in obese patients and its long-term effects in particular, is lacking. Therefore, when antihypertensives are prescribed, general recommendations for high blood pressure management and prevention of cardiovascular diseases should be followed, taking into account the so far known details of pathophysiological relationship between high blood pressure and obesity.
Keywords: hypertension; obesity; visceral fat; metabolic syndrome
Received: April 20, 2009; Published: February 1, 2009 Show citation
References
- Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Hypertension 2000; 35: 1270-1277.
- Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
Go to original source...
Go to PubMed...
- Cífková R, Skodová Z, Lánská V et al. Trends in blood pressure levels, prevalence, awarness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479-1485.
Go to original source...
Go to PubMed...
- Pelikánová T. Metabolický syndrom. Vnitř Lék 2003; 49: 900-906.
Go to PubMed...
- Kunešová M, Čechová M, Laika M. Zpráva o projektu Životní styl a obezita. Kvantitativní výzkum STEM/MARK pro MZ ČR a Českou obezitologickou společnost, 2006. Dostupné z: www.obesitas.cz/download/dospeli_web.ppt.
- Sharma AM, Grassi G. Obesity and hypertension: cause or consequence? J Hypertens 2001; 19: 2125-2126.
Go to original source...
- Allemann Y, Hutter D, Aeschbacher BC et al. Increased central body fat deposition precedes a significant rise in resting blood pressure in male offspring of essential hypertensive parents: a 5 year follow-up study. J Hypertens 2001; 19: 2143-2148.
Go to original source...
Go to PubMed...
- Garrison RJ, Kannel WB, Stokes J 3rd et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987; 16: 235-251.
Go to original source...
- Svačina Š, Owen K. Syndrom inzulínové rezistence. Praha: Triton 2003.
- Doll S, Paccaud F, Bovet P et al. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and develop countries. Int J Obes 2002; 26: 48-57.
Go to original source...
Go to PubMed...
- Kanai H, Matsuzawa Y, Kotani K et al. Close correlation of intra-abdominal fat accumulation to hypertension in obese women. Hypertension 1990; 16: 484-490.
Go to original source...
Go to PubMed...
- Unger R. The physiology of cellular liporegulation. Annu Rev Physiol 2003; 65: 333-347.
Go to original source...
Go to PubMed...
- Stevens VJ, Obarzanek E, Cook NR et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11.
Go to original source...
Go to PubMed...
- National institutes of health. Clinical quidelines on the identification, evalution, and treatment of overweight and obesity in adults - The Evidence Report. Obes Res 1998; 6 (Suppl 2): 51S-209S.
- Staessen J, Fagard R, Amery A. The relationship between body weight and blood pressure. J Hum Hypertens 1988; 2: 207-217.
Go to PubMed...
- Masuo K, Mikami M, Ogihara T et al. Differences in mechanisms between weight loss-sensitive and resistant blood pressure reduction in obese subjects. Hypertens Res 2001; 24: 371-376.
Go to original source...
Go to PubMed...
- Alvarez GE, Beske SD, Ballard TP et al. Sympathetic neural activation in visceral obesity. Circulation 2002; 106: 2533-2536.
Go to original source...
Go to PubMed...
- Sjöström CD, Peltonen M, Wedel H et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20-25.
Go to original source...
Go to PubMed...
- Blair SN, Goodyear NN, Gibbons LW et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984; 252: 487-490.
Go to original source...
Go to PubMed...
- Svačinová H. Pohybová léčba u pacientů s metabolickým syndromem. Vnitř Lék 2007; 52: 540-544.
- Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: an update. Sports Med 2000; 30: 193-206.
Go to original source...
Go to PubMed...
- Graudal NA, Galløe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta-analysis. JAMA 1998; 279: 1383-1391.
Go to original source...
Go to PubMed...
- Dengel DR, Galecki AT, Hagberg JM et al. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glukose tolerance in older men. Am J Hypertens 1998; 11: 1405-1412.
Go to original source...
Go to PubMed...
- Miller ER 3rd, Erlinger TP, Young DR et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). Hypertension 2002; 40: 612-618.
Go to original source...
Go to PubMed...
- Hauner H, Meier M, Wendland et al. Weight reduction by sibutramine in obese subjects in primary care medicine: The S.A.T. study. Exp Clin Endocrinol Diabetes 2004; 112: 201-207.
Go to original source...
Go to PubMed...
- Svačina Š. Prevence diabetu. Praha: Galén 2003.
- Derosa G, Cicero AF, Murdolo G et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005; 7: 47-55.
Go to original source...
- Sari R, Balci MK, Cakir M et al. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004; 30: 159-167.
Go to original source...
Go to PubMed...
- Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589.
Go to original source...
Go to PubMed...
- Cífková R, Horký K, Widimský J st. et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2004; 50: 709-722.
Go to PubMed...
- Reisin E, Weir MR, Falkner B et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30 (1 Pt 1): 140-145.
Go to original source...
Go to PubMed...
- Grassi G, Seravalle G, Dell'Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003; 21: 1761-1769.
Go to original source...
Go to PubMed...
- Yusuf S, Sleight P, Pogue J et al. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor Ramipril on cardiovascular events in high risk patients. N Engl J Med 2000; 324: 145-153.
Go to original source...
- Lindholm LH, Ibsen H, Dahlhöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 1004-1010.
Go to original source...
Go to PubMed...
- De Luca N, Izzo R, Fontana D et al. Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double blind parallel study versus amlodipine. J Hypertens 2000; 18: 1515-1522.
Go to original source...
Go to PubMed...
- Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. INVEST Study. JAMA 2003; 290: 2805-2816.
Go to original source...
Go to PubMed...
- Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
Go to original source...
Go to PubMed...
- Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factor for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905-912.
Go to original source...
Go to PubMed...
- Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-616.
Go to original source...
Go to PubMed...